Benzothiopyranoindole-based antiproliferative agents: Synthesis, cytotoxicity, nucleic acids interaction, and topoisomerases inhibition properties

Journal of Medicinal Chemistry

Volumn 52, Issue 17, 2009, Pages 5429-5441

  Dalla Via, Lisa ^a   Magno, Sebastiano Marciani ^a   Gia, Ornella ^a   Marini, Anna Maria ^b   Da Settimo, Federico ^b   Salerno, Silvia ^b   La Motta, Concettina ^b   Simorini, Francesca ^b   Taliani, Sabrina ^b   Lavecchia, Antonio ^c   Di Giovanni, Carmen ^c   Brancato, Giuseppe ^c   Barone, Vincenzo ^d,e   Novellino, Ettore ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d SCUOLA NORMALE SUPERIORE   (Italy)

^e AREA DELLA RICERCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BENZO[3',2':5,6]THIOPYRANO[3,2 B]INDOL 10(11H) ONE DERIVATIVE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOTOXICITY; DRUG DNA INTERACTION; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; HELA CELL; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

EID: 84961983804     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900627v     Document Type: Article

References (74)

1. Parkin, D. M. Global cancer statistics in the year 2000. Lancet Oncol. 2001, 2, 533-543.
2. Schwartsmann, G.; Ratain, M. J.; Cragg, G. M.; Wong, J. E.; Saijo, N.; Parkinson, D. R.; Fujiwara, Y.; Pazdur, R.; Newman, D. J.; Dagher, R.; Di Leone, L. Anticancer Drug Discovery and Development Throughout the World. J. Clin. Oncol. 2002, 20, 47s-59s.
3. Neidle, S.; Thurston, D. E. Chemical approaches to the discovery and development of cancer therapies. Nat. Rev. Cancer 2005, 5, 285-296.
4. Pujol, M. D.; Romero, M.; Sanchez, I. Synthesis and Biological Activity of New Class of Dioxygenated Anticancer Agents. Curr. Med. Chem. Anticancer Agents 2005, 5, 215-237.
5. Hurley, L. H. DNA and its associated processes as targets for cancer therapy. Nature Rev. Cancer 2002, 2, 188-200.
6. Zhou, B-B. S.; Bartek, J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer 2004, 4, 216-225.
7. Borowski, E.; Shugar, D. In Molecular Aspects of Chemotherapy; Pergamon Press: New York, 1991; pp 105-118.
8. Brana, M. F.; Cacho, M.; Gradillas, A.; Ramos, A. Intercalators as Anticancer Drugs. Curr. Pharm. Des. 2001, 7, 1745-1780.
9. Bischoff, G.; Hoffmann, S. DNA-Binding of Drugs Used in Medicinal Therapies. Curr. Med. Chem. 2002, 9, 321-348.
10. Denny, W. A. DNA-intercalating ligands as anti-cancer drugs: prospects for future design. Anti-Cancer Drug Des. 1989, 4, 241-263.
11. Wang, J. C. DNA topoisomerases as targets of therapeutics: an overview. In Advances in Pharmacology; Liu, L. F., Ed.; Academic Press: New York, 1994; 29A, pp 1-19.
12. Osheroff, N.; Corbett, A. H.; Robinson, M. J. Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv. Pharmacol. B 1994, 29, 105-126.
13. Capranico, G.; Zunino, F. DNA topoisomerase-trapping antitumour drugs. Eur. J. Cancer 1992, 28A, 2055-2060.
14. Gale, K. C.; Osheroff, N. Uncoupling the DNA cleavage and relegation activities of topoisomerase II with a single-stranded nucleic acid substrate: evidence for an active enzyme-cleaved DNA intermediate. Biochemistry 1990, 29, 9538-9545. (Pubitemid 20355200)
15. Wang, J. C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell. Biol. 2002, 3, 430-440.
16. Redinbo, M. R.; Stewart, L.; Kuhn, P.; Champoux, J. J.; Hol, W. G. Crystal Structures of Human Topoisomerase I in Covalent and Noncovalent Complexes with DNA. Science 1998, 279, 1504-1513.
17. Leppard, J. B.; Champoux, J. J. Human DNA topoisomerase I: relaxation, roles and damage control. Chromosoma 2005, 114, 75-85.
18. Schoeffler, A. J.; Berger, J. M. Recent advances in understanding structure-function relationships in the type II topoisomerase mechanism. Biochem. Soc. Trans. 2005, 33, 1465-1470.
19. Nitiss, J. L. DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer 2009, 9, 327-337.
20. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 1989, 58, 351-375.
21. Denny, W. A. Dual topoisomerase I/II poisons as anticancer drugs. Expert Opin. Invest. Drugs 1997, 6, 1845-1851.
22. Pommier, Y.; Tanizawa, A.; Kohn, K. W. Mechanisms of topoisomerase I inhibition by anticancer drugs. In Advances in Pharmacology; Liu L. F., Ed.; Academic Press: New York, 1994; Vol.29B, pp 73-92.
23. Holden, J. A. DNA Topoisomerases as Anticancer Drug Targets: From the Laboratory to the Clinic. Curr. Med. Chem. Anticancer Agents 2001, 1, 1-25.
24. Larsen, A. K.; Escargueil, A. E.; Skladanowski, A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacol. Ther. 2003, 99, 167-181.
25. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6, 789-802.
26. Nitiss, J. L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 2009, 9, 338-350.
27. Cozzi, P.; Mongelli, N.; Suarato, A. Recent Anticancer Cytotoxic Agents. Curr. Med. Chem. - Anti-Cancer Agents 2004, 4, 93-121.
28. Lown, J. W., Ed. Anthracycline and Anthracenedione-Based Anticancer Agents; Elsevier Science: NewYork, 1988; p 402.
29. Beretta, G. L.; Perego, P.; Zunino, F. Mechanisms of cellular resistance to camptothecins. Curr. Med. Chem. 2006, 13, 3291-3305.
30. Ryckebusch, A.; Garcin, D.; Lansiaux, A.; Goossens, J. F.; Baldeyrou, B.; Houssin, R.; Bailly, C.; Hénichart, J. P. Synthesis, Cytotoxicity, DNA Interaction, and Topoisomerase II Inhibition Properties of Novel Indeno[2,1-c]quinolin-7-one and Indeno[1,2-c]isoquinolin-5,11-dione Derivatives. J. Med. Chem. 2008, 51 (12), 3617-3629.
31. Jiménez-Alonso, S.; Chávez Orellana, H.; Estévez-Braun, A.; G. Ravelo, A.; Pérez-Sacau, E.; Machín, F. Design and Synthesis of a Novel Series of Pyranonaphthoquinones as Topoisomerase II Catalytic Inhibitors. J. Med. Chem. 2008, 51, 6761-6772.
32. Teicher, B. A. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem. Pharmacol. 2008, 75, 1262-1271.
33. Xie, L.; Qian, X.; Cui, J.; Xiao, Y.; Wang, K.; Wu, P.; Cong, L. Novel angular furoquinolinones bearing flexible chain as antitumor agent: design, synthesis, cytotoxic evaluation, and DNA-binding studies. Bioorg. Med. Chem. 2008, 16, 8713-8718.
34. Bailly, C. Topoisomerase I Poisons and Suppressors as Anticancer Drugs. Curr. Med. Chem. 2000, 7, 39-58 and references therein.
35. Baguley, B. C. DNA intercalating anti-tumour agents. Anti-Cancer Drug Des. 1991, 6, 1-35.
36. Capranico, G.; Zunino, F. Antitumor Inhibitors of DNA Topoisomerases. Curr. Pharm. Des. 1995, 1, 1-14.
37. Da Settimo, A.; Da Settimo, F.; Marini, A. M.; Primofiore, G.; Salerno, S.; Viola, G.; Dalla Via, L.; Marciani Magno, S. Synthesis, DNA binding and in vitro antiproliferative activity of purinoquinazoline, pyridopyrimidopurine and pyridopyrimidobenzimidazole derivatives as potential antitumor agents. Eur. J. Med. Chem. 1998, 33, 685-696.
38. Dalla Via, L.; Gia, O.; Marciani Magno, S.; Da Settimo, A.; Marini, A. M.; Primofiore, G.; Da Settimo, F.; Salerno, S. Synthesis, in vitro antiproliferative activity and DNA-interaction of benzimidazoquinazoline derivatives as potential anti-tumor agents. Il Farmaco 2001, 56, 159-167.
39. Dalla Via, L.; Gia, O.; Marciani Magno, S.; Da Settimo, A.; Primofiore, G.; Simorini, F.; Marini, A. M.; Da Settimo, F. Dialkylaminoalkylindolonaphthyridines as potential antitumour agents: synthesis, cytotoxicity and DNA binding properties. Eur. J. Med. Chem. 2002, 37, 475-486.
40. Dalla Via, L.; Marini, A. M; Salerno, S.; Toninello, A. Mitochondrial permeability transition induced by novel pyridothiopyranopyrimidine derivatives: potential new antimitochondrial antitumour agents. Biochem. Pharmacol. 2006, 72, 1657-1667.
41. Dalla Via, L.; Marini, A. M.; Salerno, S.; La Motta, C.; Condello, M.; Arancia, G.; Agostinelli, E.; Toninello, A. Synthesis and biological activity of 1,4-dihydrobenzothiopyrano[4,3-c]pyrazole derivatives, novel pro-apoptotic mitochondrial targeted agents. Bioorg. Med. Chem. 2009, 17, 326-336.
42. Phillips, R. R. Org. Reactions 1959, 10, 143-178.
43. Marechal, R.; Bagot, J. Muscarine-like action of some halogenated derivatives of alkyltrimethylammoniums (homologs of bromocholine). II. Chemistry. Ann. Pharm. Fr. 1946, 4, 172-181.
44. (a) Di Noto, V.; Dalla Via, L.; Toninello, A.; Vidali, M. Thermodynamic treatment of ligand-receptor interactions. Macromol. Theory Simul. 1996, 5, 165-181.
45. (b) Di Noto, V.; Dalla Via, L.; Zatta, P. Review of binding methods and detection of Al(III) binding events in trypsin and DL-DPPC liposomes by a general thermodynamic model. Coord. Chem. Rev. 2002, 228, 343-363.
46. Caceres-Cortes, J.; Sugiyama, H.; Ikudome, K.; Saito, I.; Wang, A. H.-J. Interactions of Deglycosylated Cobalt(III)-Pepleomycin (Green Form) with DNA Based on NMR Structural Studies. Biochemistry 1997, 36, 9995-10005.
47. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated Docking Using a Lamarckian Genetic Algorithm and an Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
48. Case, D. A.; Darden, T. A.; Cheatham, T. E., III; Simmerling, C. L.; Wang, J.; Duke, R. E.; Luo, R.; Merz, K. M.; Pearlman, D. A.; Crowley, M.; Walker, R. C.; Zhang, W.; Wang, B.; Hayik, S.; Roitberg, A.; Seabra, G.; Wong, K. F.; Paesani, F.; Wu, X.; Brozell, S.; Tsui, V.; Gohlke, H.; Yang, L.; Tan, C.; Mongan, J.; Hornak, V.; Cui, G.; Beroza, P.; Mathews, D. H.; Schafmeister, C.; Ross, W. S.; Kollman, P. A. AMBER, version 9; University of California: San Francisco, CA, 2006.
49. Wang, J. M.; Cieplak, P.; Kollman, P. A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 2000, 21, 1049-1074.
50. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general Amber force field. J. Comput. Chem. 2004, 25, 1157-1174.
51. (a) Becke, A. D. Density-functional thermochemistry. III. The role of exact exchange. J. Chem. Phys. 1993, 98, 5648-5652.
52. (b) Stephens, P. J.; Devlin, F. J.; Chabalowski, C. F.; Frisch, M. J. Ab initio calculation of vibrational absorption and circular dichroism spectra using density functional force fields. J. Phys. Chem. 1994, 98, 11623-11627.
53. Grimme, S. Improved Second-Order Møller-Plesset Perturbation Theory by Separate Scaling of Parallel- and Antiparallel-Spin Pair Correlation Energies. J. Chem. Phys. 2003, 118, 9095-9102.
54. Pavone, M.; Rega, N.; Barone, V. Implementation and validation of DFT-D for molecular vibrations and dynamics: The benzene dimer as a case study. Chem. Phys. Lett. 2008, 452, 333-339.
55. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; Montgomery, J., J. A.; Vreven, T.; Kudin, K. N.; Burant, J. C.; Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V.; Mennucci, B.; Cossi, M.; Scalmani, G.; Rega, N.; Petersson, G. A.; Nakatsuji, H.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. P.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Ayala, P. Y.; Morokuma, K.; Voth, G. A.; Salvador, P.; Dannenberg, J. J.; Zakrzewski, V. G.; Dapprich, S.; Daniels, A. D.; Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; Foresman, J. B.; Ortiz, J. V.; Cui, Q.; Baboul, A. G.; Clifford, S.; Cioslowski, J.; Stefanov, B. B.; Liu, G.; Liashenko, A.; Piskorz, P.; Komaromi, I.; Martin, R. L.; Fox, D. J.; Keith, T.; Al. Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; Challacombe, M.; Gill, P. M. W.; Johnson, B.; Chen, W.; Wong, M. W.; Gonzalez, C.; Pople, J. A. Gaussian 03, revision C.02; Gaussian, Inc.: Wallingford, CT, 2004.
56. (a) Klamt, A.; Schurmann, G. COSMO: a new approach to dielectric screening in solvents with explicit expressions for the screening energy and its gradient. J. Chem. Soc., Perkin Trans. 2 1993, 2, 799-805.
57. (b) Barone, V.; Cossi, M. J. Quantum calculation of molecular energy gradients in solution by a conductor solvent model. J. Phys. Chem. A 1998, 102, 1995-2001.
58. Miertus, S.; Scrocco, E.; Tomasi, J. Electrostatic interaction of a solute with a continuum. A direct utilization of ab initio molecular potentials for the prevision of solvent effects. Chem. Phys. 1981, 55, 117-129.
59. Xiao, X.; Antony, S.; Pommier, Y.; Cushman, M. On the Binding of Indeno[1,2-c]isoquinolines in the DNA-Topoisomerase I Cleavage Complex. J. Med. Chem. 2005, 48, 3231-3238.
60. Chen, A. Y.; Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 1994, 34, 191-218.
61. Watt, P. M.; Hickson, I. D. Structure and function of type II topoisomerases. Biochem. J. 1994, 303, 681-695. (Pubitemid 24325996)
62. Antony, S.; Agama, K. K.; Miao, Z.-H.; Hollingshead, M.; Holbeck, S. L.; Wright, M. H.; Varticovski, L.; Nagarajan, M.; Morrell, A.; Cushman, M.; Pommier, Y. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H- indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol. Pharmacol. 2006, 70, 1109-1120.
63. Harker, W. G.; Slade, D. L.; Drake, F. H.; Parr, R. L. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II β isoform. Biochemistry 1991, 30, 9953-9961.
64. Denny, W. A.; Baguley, B. C. Dual topoisomerase I/II in Cancer Therapy. Curr. Top. Med. Chem. 2003, 3, 1349-1364, and references therein.
65. Marmur, J.; Doty, P. Determination of the base composition of the deoxyribonucleic acid from its thermal denaturation temperature. J. Mol. Biol. 1962, 5, 109.
66. Wada, A.; Kozawa, S. Instrument for the studies of differential flow dichroism of polymer solutions. J. Polym. Sci., Part A: Polym. Chem. 1964, 2, 853-864.
67. (a) MacroModel version 9.0; Schrodinger Inc.: Portland, OR, 1998-2001.
68. (b) Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Lipton, M.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. MacroModel-an integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J. Comput. Chem. 1990, 11, 440-467.
69. (a) Kaminski, G. A.; Friesner, R. A.; Tirado-Rives, J.; Jorgensen, W. J. Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J. Phys. Chem. B 2001, 105, 6474-6487.
70. (b) Jorgensen, W. L.; Tirado-Rives, J. The OPLS Potential Functions for Proteins. Energy Minimization for Crystals of Cyclic Peptides and Crambin. J. Am. Chem. Soc. 1988, 110, 1657-1666.
71. Pymol version 0.98. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano-Scientific: San Carlos, CA, 2002; www.pymol.org.
72. Allen, F. H.; Bellard, S.; Brice, M. D.; Cartwright, B. A.; Doubleday, A.; Higgs, H.; Hummelink, T.; Hummelink-Peters, B. G.; Kennard, O.; Motherwell, W. D. S. The Cambridge crystallographic data center: computer-based search, retrieval, analysis and display of information. Acta Crystallogr., Sect. B: Struct. Sci. 1979, 35, 2331-2339.
73. (a) Huey, R.; Morris, G. M.; Olson, A. J.; Goodsell, D. S. A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 2007, 28, 1145-1152.
74. (b) Alonso, H.; Bliznyuk, A. A.; Gready, J. E. Combining docking and molecular dynamic simulations in drug design. Med. Res. Rev. 2006, 26, 531-568.